Cas:88901-37-5 Mogroside III-E manufacturer & supplier

Chemical Name:Mogroside III-E

CAS.NO:88901-37-5

Synonyms:β-D-Glucopyranoside, (1R,4R)-4-[(3β,9β,11α,17β)-3-(β-D-glucopyranosyloxy)-11-hydroxy-4,4,9,14-tetramethylestr-5-en-17-yl]-1-(1-hydroxy-1-methylethyl)pentyl 2-O-β-D-glucopyranosyl -;(1S,4S,9β,11α,24R)-1-(β-D-Glucopyranosyloxy)-11,25-dihydroxy-9,10,14-trimethyl-4,9-cyclo-9,10-secocholest-5-en-24-yl 2-O-β-D-glucopyranosyl-β-D-glucopyranoside;(1S,4R,8β,9β,11α,24R)-1-(β-D-Glucopyranosyloxy)-11,25-dihydroxy-9,10,14-trimethyl-4,9-cyclo-9,10-secocholest-5-en-24-yl 2-O-β-D-glucopyranosyl-β-D-glucopyranoside;β-D-Glucopyranoside, (1R,4R)-4-[(3β,8α,9β,10α,11α,17β)-3-(β-D-glucopyranosyloxy)-11-hydroxy-4,4,9,14-tetramethylestr-5-en-17-yl]-1-(1-hydroxy-1-methylethyl)pentyl 2-O-β-D
 -glucopyranosyl-;mogroside Ⅲe;Mogroside III-E

Molecular Formula:C₄₈H₈₂O₁₉

Molecular Weight:963.153

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:1050.4±65.0 °C at 760 mmHg

Density:1.4±0.1 g/cm3

Index of Refraction:1.619

PSA:318.37000

Exact Mass:962.545044

LogP:1.70

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like β-D-Glucopyranoside, (1R,4R)-4-[(3β,9β,11α,17β)-3-(β-D-glucopyranosyloxy)-11-hydroxy-4,4,9,14-tetramethylestr-5-en-17-yl]-1-(1-hydroxy-1-methylethyl)pentyl 2-O-β-D-glucopyranosyl – chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,Mogroside III-E physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,mogroside Ⅲe Use and application,-glucopyranosyl- technical grade,usp/ep/jp grade.

Related News: With the onset of the DMF system for APIs, the concentration of the API industry will further increase. Mogroside III-E manufacturer With the improvement of people’s living standards and the aging degree, the demand for medicines has been increasing for a long time. Therefore, the transfer from finished medicines to bulk medicines has greatly promoted the demand for bulk medicines. Mogroside III-E supplier With the onset of the DMF system for APIs, the concentration of the API industry will further increase. Mogroside III-E vendor With the improvement of people’s living standards and the aging degree, the demand for medicines has been increasing for a long time. Therefore, the transfer from finished medicines to bulk medicines has greatly promoted the demand for bulk medicines. Mogroside III-E factory Madeleine Roche, Associate Pharmaceutical Analyst at GlobalData, comments: ��Within the top 20 global companies that spent the most on R&D in 2018, the top spender �C despite having the second smallest annual revenue of the group at $15.28 billion �C is Celgene, whose R&D spend was equal to 37% of its annual revenue.